Recent Updates — SINT
Following a call notice issued on October 1, 2026, Sintx Technologies received aggregate gross proceeds of $2,014,645.22 from the exercise and exchange of 941,423 Class B Common Stock Purchase Warrants at an effective price of $2.14 per share. The company issued 651,204 shares of common stock and fully pre-funded warrants for 290,219 additional shares to comply with beneficial ownership limitations. The remaining warrants expired without consideration, leaving no Class B warrants outstanding. Post-transaction, the company has 7,558,073 shares of common stock outstanding as of October 9, 2026. Sintx Technologies operates in the semiconductor industry, specializing in thermal management solutions.
SINTX Technologies reported preliminary unaudited revenue of $2.2 million for the quarter ended September 30, 2026, significantly exceeding its previous guidance range of $0.9 million to $1.1 million and representing approximately 380% growth from the second quarter. The company intends to deliver a Call Notice to holders of Class B Common Stock Purchase Warrants, as roughly $2.1 million in product sales triggered the warrant call right requiring quarterly revenue of at least $2.0 million. This action could result in up to $4.0 million in additional capital if approximately 1.88 million warrants are exercised. SINTX Technologies operates in the advanced ceramics and biomaterials industry, developing silicon nitride technologies for medical devices and industrial applications.
SINTX Technologies, Inc. received written notification from Nasdaq confirming it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1). Based on its Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, the company satisfied the $2.5 million threshold. Nasdaq determined that the previously disclosed deficiency matter is now closed. SINTX Technologies operates in the advanced ceramics industry, developing and commercializing silicon nitride biomaterials and medical devices.
SINTX Technologies provided a mid-year business update for the period ended June 30, 2026. The company raised approximately $5.0 million in gross proceeds through private placement and ATM sales during Q2. It received roughly $3.2 million in new industrial purchase orders with revenue recognition expected starting in Q3 2026. Management issued revenue guidance of $900,000 to $1.1 million for Q3 and $1.0 million to $1.3 million for Q4 2026. The company advanced commercialization of its FDA-cleared SiNAPTIC Foot & Ankle Implant System via a Limited Use Release and established a distributor network. Additionally, SINTX completed construction of an advanced 3D printing facility and secured an extension on NIH grant funding. SINTX Technologies operates in the advanced ceramics industry, developing silicon nitride biomaterials and medical devices for orthopedic applications.
SINTX Technologies, Inc. has engaged Southern Metrics Consulting to establish a Strategic Opportunity Management Program to identify, evaluate, and pursue strategic opportunities such as commercial partnerships, licensing, joint ventures, and acquisitions to enhance stockholder value. The program is led by board member Chris Lyons, who serves as CEO of Southern Metrics. SINTX Technologies, Inc. is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials and medical devices for medical and industrial applications.
Sintx Technologies, Inc. entered into a letter agreement with MedTech Ceramics, LP to restructure a previous warrant inducement transaction from September 2025. The agreement involves issuing 255,267 shares of common stock from abeyance and replacing the remaining 251,987 abeyance shares with a pre-funded warrant, while also replacing an existing warrant with a new warrant to purchase 1,268,135 shares at $2.14 per share. Sintx Technologies, Inc. operates in the medical technology industry, providing advanced ceramic materials for medical applications.